Trials / Unknown
UnknownNCT03631576
CD123/CLL1 CAR-T Cells for R/R AML (STPHI_0001)
CD123/CLL1 CAR-T Cell Therapy for Relapsed and Refractory Acute Myeloid Leukemia
- Status
- Unknown
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- Fujian Medical University · Academic / Other
- Sex
- All
- Age
- 70 Years
- Healthy volunteers
- Not accepted
Summary
The treatment options for relapse/refractory B-cell acute myeloid leukemia(AML)are limited.CD123/CLL1 CAR-T Cells may have a permanent anti-tumor effect and became very attractive. This study aims to assess the safety and toxicity of CD123/CLL1 CAR-T Cells to patients with relapse/refractory AML.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | CD123/CLL1 CAR-T Cells | CD123/CLL1 CAR-T Cell Therapy |
Timeline
- Start date
- 2018-08-10
- Primary completion
- 2021-08-10
- Completion
- 2021-08-10
- First posted
- 2018-08-15
- Last updated
- 2020-01-02
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03631576. Inclusion in this directory is not an endorsement.